$285.09
1.09% yesterday
NYSE, Aug 11, 10:02 pm CET
ISIN
US0311621009
Symbol
AMGN

Amgen Stock price

$285.09
-10.18 3.45% 1M
-11.57 3.90% 6M
+24.45 9.38% YTD
-34.91 10.91% 1Y
+36.74 14.79% 3Y
+50.44 21.50% 5Y
+116.53 69.13% 10Y
+204.25 252.66% 20Y
NYSE, Closing price Mon, Aug 11 2025
-3.14 1.09%
ISIN
US0311621009
Symbol
AMGN
Industry

Key metrics

Basic
Market capitalization
$153.5b
Enterprise Value
$201.7b
Net debt
$48.2b
Cash
$8.0b
Shares outstanding
538.0m
Valuation (TTM | estimate)
P/E
23.3 | 13.4
P/S
4.4 | 4.3
EV/Sales
5.8 | 5.6
EV/FCF
16.8
P/B
20.7
Dividends
DPS
$9.00
Yield 1Y | 5Y
3.2% | 3.1%
Growth 1Y | 5Y
5.6% | 9.2%
Payout 1Y | 3Y
119.1% | 78.6%
Increased
14 Years
Financials (TTM | estimate)
Revenue
$34.9b | $36.1b
EBITDA
- | $20.8b
EBIT
$10.9b | $15.9b
Net Income
$6.6b | $11.5b
Free Cash Flow
$12.0b
Growth (TTM | estimate)
Revenue
12.9% | 8.0%
EBITDA
- | 36.7%
EBIT
75.2% | 65.1%
Net Income
111.5% | 180.2%
Free Cash Flow
119.2%
Margin (TTM | estimate)
Gross
69.7%
EBITDA
- | 57.8%
EBIT
31.3%
Net
19.0% | 31.8%
Free Cash Flow
34.4%
Financial Health
Equity Ratio
6.4%
Return on Equity
69.6%
ROCE
16.2%
ROIC
-
Debt/Equity
7.6
More
EPS
$12.2
FCF per Share
$22.3
Short interest
2.7%
Employees
28k
Rev per Employee
$1.2m
Show more

Create a Free Account to create an Amgen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Amgen Stock Analysis

Unlock Scores for Free

Analyst Opinions

39 Analysts have issued a Amgen forecast:

21x Buy
54%
15x Hold
38%
3x Sell
8%

Analyst Opinions

39 Analysts have issued a Amgen forecast:

Buy
54%
Hold
38%
Sell
8%

Financial data from Amgen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
34,917 34,917
13% 13%
100%
- Direct Costs 10,578 10,578
7% 7%
30%
24,339 24,339
24% 24%
70%
- Selling and Administrative Expenses 6,840 6,840
5% 5%
20%
- Research and Development Expense 6,345 6,345
18% 18%
18%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 10,928 10,928
75% 75%
31%
Net Profit 6,619 6,619
111% 111%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Amgen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amgen Stock News

Positive
Seeking Alpha
5 days ago
Verizon is the only Dow stock currently meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are supported by free cash flow. Analyst forecasts suggest top Dow dividend stocks could deliver 14.93% to 41.48% net gains by August 2026, with an average estimated gain of 23.33%. Most Dow stocks remain overpriced relative to their dividends, but market pullbac...
Positive
Seeking Alpha
6 days ago
Amgen delivered strong Q2 2025 results, beating expectations and raising full-year guidance, driven by robust growth in key products despite Enbrel's decline. MariTide, Amgen's promising obesity/diabetes pipeline candidate, shows strong efficacy but will take years to significantly impact revenue; market growth may moderate. Debt remains elevated post-Horizon acquisition, limiting share buyback...
Neutral
Seeking Alpha
6 days ago
Amgen Inc. (NASDAQ:AMGN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants & - Corporate Participant James E. Bradner - Executive Vice President of Research Development Justin G.
More Amgen News

Company Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Head office United States
CEO Robert Bradway
Employees 28,000
Founded 1980
Website www.amgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today